Research Article

Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors

Volume: 7 Number: 1 January 31, 2023
EN

Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors

Abstract

Purpose: Abnormal Sonic Hedgehog signaling Pathway (Shh) activation is crucial for development of cancer stem cells, neoplastic growth and epithelial-mesenchymal transition processes in adulthood. Activation of Hedgehog signaling pathway may induces the changes in cilia found in the cell membrane, iniciates the Gli1 transcription factor that is translocated to the cell nucleus and finally, the target genes are transcribed. In this study, invastigation of the antiproliferative, anti-invasive and antimigrative effect of the combined use of robotnikinin (Ptch1 antagonist) and vismodegib (Smo inhibitor) on the hedgehog signaling pathway was aimed. Material and Methods: After demonstarting the presence of the hedgehog signaling pathway in the glioblastoma cell line U87-MG, the effect of the combined use of the robotnikinin and the vismodegib on the hedgehog signaling pathway was investigated. In-vitro cell proliferation, migration, and invasion analysis of the combination of antagonist and inhibitor and in silico drug-likeness analysis were performed. Results: Two different combinations of robotnikinin and vismodegib were tested. In vitro studies show that the combined use of agents in combined treatments of Smo and Ptch1is more effective than their individual usage. Conclusion: Inhibition of the hedgehog signaling pathway with specific inhibitors and antagonists is considered an innovative strategy for cancer therapy.

Keywords

Supporting Institution

Dokuz Eylul University, Scientific Research Coordination Unit

Project Number

2020.KB.SAG.021

Thanks

We sincerely thank Asım Leblebici for his support during the entire study process

References

  1. (1) Nüsslein-volhard C, Wieschaus E. Mutations affecting segment number and polarity in drosophila. Nature. 1980; 287(5785):795-801
  2. (2) Ingham PW, McMahon AP. Hedgehog signaling in animal development: Paradigms and principles. Genes and Development. 2001; 15(23):3059-87
  3. (3) Petrova R, Joyner AL. Roles for Hedgehog signaling in adult organ homeostasis and repair. Development (Cambridge). 2014; 141(18):3445-57
  4. (4) Singh BN, Fu J, Srivastava RK, Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS One. 2011; 6(11):e27306
  5. (5) Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and Tumorigenicity. Curr Biol. 2007; 17(2):165-72
  6. (6) Meng E, Hanna A, Samant RS, Shevde LA. The impact of hedgehog signaling pathway on DNA repair mechanisms in human cancer. Cancers. 2015; 7(3):1333-48
  7. (7) Lézot F, Corre I, Morice S, Rédini F, Verrecchia F. SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression. Cells. 2020; 9(3):536
  8. (8) Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, et al. TGF-β promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 2011; 71(3):822-31

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

January 31, 2023

Submission Date

October 24, 2022

Acceptance Date

December 30, 2022

Published in Issue

Year 2023 Volume: 7 Number: 1

APA
Karadağ, A., & Başbınar, Y. (2023). Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors. Journal of Basic and Clinical Health Sciences, 7(1), 492-500. https://doi.org/10.30621/jbachs.1193720
AMA
1.Karadağ A, Başbınar Y. Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors. JBACHS. 2023;7(1):492-500. doi:10.30621/jbachs.1193720
Chicago
Karadağ, Aslıhan, and Yasemin Başbınar. 2023. “Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors”. Journal of Basic and Clinical Health Sciences 7 (1): 492-500. https://doi.org/10.30621/jbachs.1193720.
EndNote
Karadağ A, Başbınar Y (January 1, 2023) Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors. Journal of Basic and Clinical Health Sciences 7 1 492–500.
IEEE
[1]A. Karadağ and Y. Başbınar, “Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors”, JBACHS, vol. 7, no. 1, pp. 492–500, Jan. 2023, doi: 10.30621/jbachs.1193720.
ISNAD
Karadağ, Aslıhan - Başbınar, Yasemin. “Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors”. Journal of Basic and Clinical Health Sciences 7/1 (January 1, 2023): 492-500. https://doi.org/10.30621/jbachs.1193720.
JAMA
1.Karadağ A, Başbınar Y. Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors. JBACHS. 2023;7:492–500.
MLA
Karadağ, Aslıhan, and Yasemin Başbınar. “Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors”. Journal of Basic and Clinical Health Sciences, vol. 7, no. 1, Jan. 2023, pp. 492-00, doi:10.30621/jbachs.1193720.
Vancouver
1.Aslıhan Karadağ, Yasemin Başbınar. Novel Approach to the Hedgehog Signaling Pathway: Combined Treatment of SMO and PTCH Inhibitors. JBACHS. 2023 Jan. 1;7(1):492-500. doi:10.30621/jbachs.1193720

Cited By